The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses a subgroup analysis of the DREAMM-7 ( NCT04246047) and DREAMM-8 (NCT04484623) trials, evaluating outcomes with belantamab mafodotin in functional high-risk relapsed/refractory multiple myeloma (RRMM). Dr Beksac highlights encouraging outcomes for these patients who currently have an unmet need, and recommends that CAR T-cells or belantamab combinations are good treatment options for this patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
